Relation of dose of carvedilol to reduction in QT dispersion in patients with mild to moderate heart failure secondary to ischemic or to idiopathic dilated cardiomyopathy.
Carvedilol has been shown to improve survival and morbidity in patients with heart failure. It has been demonstrated that carvedilol use is associated with dose-dependent reduction in QT dispersion (QTd) independent of the cause of heart failure, suggesting that reduction in QTd may be a mechanism by which carvedilol improves outcomes in heart failure.
Pittenger
Basil
B
Department of Medicine, Division of Cardiology, University of Washington, Seattle 98195-9748, USA.
Gill
Edward A
EA
Holcslaw
Terry L
TL
Bristow
Michael R
MR
D000293:Adolescent; D000317:Adrenergic alpha-Antagonists / Q000008:administration & dosage* / Q000494:pharmacology*; D000328:Adult; D000368:Aged; D002227:Carbazoles / Q000008:administration & dosage* / Q000494:pharmacology*; D000077261:Carvedilol; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004562:Electrocardiography; D005260:Female; D006333:Heart Failure / Q000188:drug therapy*; D006339:Heart Rate / Q000187:drug effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010919:Placebos; D011412:Propanolamines / Q000008:administration & dosage* / Q000494:pharmacology*
D000317:Adrenergic alpha-Antagonists; D002227:Carbazoles; D010919:Placebos; D011412:Propanolamines; D000077261:Carvedilol